<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1645">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139745</url>
  </required_header>
  <id_info>
    <org_study_id>BTL-899_CTUS400</org_study_id>
    <nct_id>NCT05139745</nct_id>
  </id_info>
  <brief_title>Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue</brief_title>
  <official_title>Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTL Industries Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTL Industries Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and performance of the BTL-899 device for non-invasive&#xD;
      treatment of subcutaneous fat. The changes in the fat tissue related to the activity of&#xD;
      caspase-3 will be assessed histologically. The study is a prospective single-center&#xD;
      single-blinded two-arm study. The subjects will be enrolled and assigned into two study&#xD;
      groups; Group A which will receive active treatment and Group B which receives sham treatment&#xD;
      and will serve as a control to verify the treatment outcomes. Subjects will be required to&#xD;
      complete only one (1) treatment visit and three (3) follow-up visits (at 8 hours, 24 hours&#xD;
      and 7 days post treatment). All of the study subjects will receive the treatment (either&#xD;
      active or sham) with the subject device.&#xD;
&#xD;
      At the baseline visit, health status will be assessed. Inclusion and exclusion criteria will&#xD;
      be verified and informed consent will be signed. Punch biopsies from the treated abdominal&#xD;
      area will be taken to examine the changes related to caspase-3 activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased caspase-3 activity</measure>
    <time_frame>1 month</time_frame>
    <description>Biopsy samples of the abdominal fat tissue will be processed for histological evaluation by a certified laboratory. Conventional staining will be used to determine the changes in the fat tissue related to the increase in caspase-3 activity, which is associated with elevated levels of fat tissue apoptosis, and to examine other morphological changes of treated tissue, in all collected samples. Post-treatment findings will be compared to the baseline. The results of both study groups will be compared as well.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>1 month</time_frame>
    <description>Occurrence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Fat Burn</condition>
  <arm_group>
    <arm_group_label>Histological evaluation of BTL-899 device´s effect on fat tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be treated with 100% of the treatment parameter settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will be treated with 5% of the treatment parameter settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BTL-899</intervention_name>
    <description>BTL-899 treatment</description>
    <arm_group_label>Histological evaluation of BTL-899 device´s effect on fat tissue</arm_group_label>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 21 years&#xD;
&#xD;
          -  Voluntarily signed an informed consent form&#xD;
&#xD;
          -  BMI ≤ 35 kg/m2&#xD;
&#xD;
          -  Women of child-bearing potential are required to use birth control measures during the&#xD;
             whole duration of the study.&#xD;
&#xD;
          -  Willingness to abstain from partaking in any treatments other than the study procedure&#xD;
&#xD;
          -  Willingness to comply with study instructions, to return to the clinic for the&#xD;
             required visits and to undergo punch biopsies in the abdominal area.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators)&#xD;
&#xD;
          -  Metal implants in the treated area&#xD;
&#xD;
          -  Drug pumps&#xD;
&#xD;
          -  Malignant tumor&#xD;
&#xD;
          -  Pulmonary insufficiency&#xD;
&#xD;
          -  Injured or otherwise impaired muscles in the treated area&#xD;
&#xD;
          -  Cardiovascular diseases&#xD;
&#xD;
          -  Disturbance of temperature or pain perception&#xD;
&#xD;
          -  Hemorrhagic conditions&#xD;
&#xD;
          -  Septic conditions and empyema&#xD;
&#xD;
          -  Acute inflammations in the treated area&#xD;
&#xD;
          -  Systemic or local infection such as osteomyelitis and tuberculosis&#xD;
&#xD;
          -  Contagious skin disease&#xD;
&#xD;
          -  Elevated body temperature&#xD;
&#xD;
          -  Application during pregnancy, postpartum period, nursing, and menstruation&#xD;
&#xD;
          -  Graves' disease&#xD;
&#xD;
          -  Skin related autoimmune diseases that may contradict the biopsy&#xD;
&#xD;
          -  Poor healing and unhealed wounds in the treatment area&#xD;
&#xD;
          -  Any disease or condition contradicting the skin tissue biopsy&#xD;
&#xD;
          -  Any disease or condition that may compromise the histologic observation at the&#xD;
             pathologist discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Georgi Petkov</last_name>
    <phone>+359 32 622 252</phone>
    <email>petkov@btl.bg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialist, a Division of Schweiger Dermatology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J Goldberg, MD</last_name>
      <phone>609-219-5621</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

